Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study

• References

• 1 Ten Cate H. Monitoring new oral anticoagulants, managing thrombosis, or both?. Thromb Haemost 2012; 107: 803-805.
• 2 Lindahl TL, Baghaei F, Faberberg Blixter I. et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-378.
• 3 Hillarp A, Bahaei F, Faberberg Blixter I. et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 09: 133-139.
• 4 Harenberg J, Marx S, Erdle S. et al. Determination of the anticoagulant effects of new oral anticoagulants: an unmet need. Expert Rev Hematol 2012; 05: 107-113.
• 5 Pengo V, Tripodi A, Reber G. et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 10: 1737-1740.
• 6 Douxfils J, Mullier F, Robert S. et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etixylate. Thromb Haemost 2012; 107: 985-997.
• 7 Favaloro EJ, Mirochnik O, McDonald D. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with dRVVT than with APTT based assays. Br J Biomed Sci 1999; 56: 23-33.
• 8 Rylatt DB, Hohnen-Behrens C, Pilgrim RL. et al. Detecting APC-resistant factor V: a functional method without plasma dilution. Blood Coagul Fibrinolysis 1999; 10: 359-366.
• 9 Haas FJ, van Sterckenburg-Kamp BM, Scheepers HA. A protein C pathway screening test for the detection of APC resistance and protein C or S deficiencies. Semin Thromb Hemost 1998; 24: 355-362.